COMPANY

MAIA Biotechnology

HQ: Chicago, IL source · maiabiotech.com ↗ · Midwest

Clinical Phase 3

Keywords: cancer oncology immuno-oncology Non-Small-Cell Lung Carcinoma advanced non-small cell lung cancer

Location: Chicago, IL · source · Oct 15, 2026

Profile checked Oct 10, 2026

$45.3MRaised (2 yrs)2Trials (company is sponsor)2NIH grants

Funding and NIH signals

NIH award NIH awarded $770K (SBIR Phase II 5R44CA309843-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA309843-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44CA309843-02
  Organization: MAIA BIOTECHNOLOGY, INC.; City/State: CHICAGO, IL; Project number: 5R44CA309843-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 770168; Administering IC: National Cancer Institute; Project title: Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Mar 4, 2026 Raise Follow-on offering: $30M (total, as published), announced Mar 4, 2026. Source: SEC filing. source ↗
Dec 24, 2025 Raise Private placement: $1.51M (total, as published), announced Dec 24, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Jan 5, 2026 SEC Form D ↗
Dec 16, 2025 Raise Private placement: $1.51M (total, as published), announced Dec 16, 2025. Source: SEC filing. source ↗
Dec 8, 2025 Trial start III: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC source ↗
Oct 13, 2025 Raise Private placement: $736,600 (total, as published), announced Oct 13, 2025. Source: SEC filing. source ↗
Sep 29, 2025 Raise Private placement: $2.25M (total, as published), announced Sep 29, 2025. Source: SEC filing. source ↗
Sep 24, 2025 Grant Government grant: $2.3M (total, as published), announced Sep 24, 2025. Source: SEC filing. source ↗
May 27, 2025 Raise Private placement: $695,000 (total, as published), announced May 27, 2025. Source: SEC filing. source ↗
May 5, 2025 Raise Private placement: $1.08M (total, as published), announced May 5, 2025. Source: SEC filing. source ↗
Feb 24, 2025 Raise Private placement: $1.43M (total, as published), announced Feb 24, 2025. Source: SEC filing. source ↗
Feb 18, 2025 Raise Private placement: $2.71M (total, as published), announced Feb 18, 2025. Source: SEC filing. source ↗
Dec 9, 2024 Raise Private placement: $950,000 (total, as published), announced Dec 9, 2024. Source: SEC filing. source ↗
Oct 28, 2024 Raise Private placement: $2.44M (total, as published), announced Oct 28, 2024. Source: SEC filing. source ↗
Jun 8, 2022 Trial start Phase 2: THIO Sequenced With Cemiplimab in Advanced NSCLC source ↗

Upcoming milestones

Jul 31, 2027 (ESTIMATED) · III · A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC · NCT06908304
Sep 30, 2027 (ESTIMATED) · Phase 2 · THIO Sequenced With Cemiplimab in Advanced NSCLC · NCT05208944

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $45.3M. Last 2 years.

Mar 4, 2026 Follow-on offering: $30M (total, as published), announced Mar 4, 2026. Source: SEC filing. source ↗
Dec 24, 2025 Private placement: $1.51M (total, as published), announced Dec 24, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Jan 5, 2026 SEC Form D ↗
Dec 16, 2025 Private placement: $1.51M (total, as published), announced Dec 16, 2025. Source: SEC filing. source ↗
Oct 13, 2025 Private placement: $736,600 (total, as published), announced Oct 13, 2025. Source: SEC filing. source ↗
Sep 29, 2025 Private placement: $2.25M (total, as published), announced Sep 29, 2025. Source: SEC filing. source ↗
May 27, 2025 Private placement: $695,000 (total, as published), announced May 27, 2025. Source: SEC filing. source ↗
May 5, 2025 Private placement: $1.08M (total, as published), announced May 5, 2025. Source: SEC filing. source ↗
Feb 24, 2025 Private placement: $1.43M (total, as published), announced Feb 24, 2025. Source: SEC filing. source ↗
Feb 18, 2025 Private placement: $2.71M (total, as published), announced Feb 18, 2025. Source: SEC filing. source ↗
Dec 9, 2024 Private placement: $950,000 (total, as published), announced Dec 9, 2024. Source: SEC filing. source ↗
Oct 28, 2024 Private placement: $2.44M (total, as published), announced Oct 28, 2024. Source: SEC filing. source ↗
Sep 24, 2025 Government grant: $2.3M (total, as published), announced Sep 24, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05208944	THIO Sequenced With Cemiplimab in Advanced NSCLC	Phase 2	Active, not recruiting	Jun 8, 2022	Sep 30, 2027 (estimated)
NCT06908304	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	III	Recruiting	Dec 8, 2025	Jul 31, 2027 (estimated)

NIH awards 2

Annual award amounts. Total $1.5M.

Sep 17, 2026 NIH award 5R44CA309843-02 FY2026: $770,168 awarded for that fiscal year; activity R44 (SBIR); PI ZAPOROJAN, VICTOR; recipient as written: MAIA BIOTECHNOLOGY, INC., CHICAGO, IL. Novel Telomere-Targeting Therapy for Ad source ↗
Sep 8, 2025 NIH award 1R44CA309843-01 FY2025: $770,168 awarded for that fiscal year; activity R44 (SBIR); PI ZAPOROJAN, VICTOR; recipient as written: MAIA BIOTECHNOLOGY, INC., CHICAGO, IL. Novel Telomere-Targeting Therapy for Ad source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-01-05 Raise Private raise (SEC Form D): $1.5M sold of $2.0M offered; issuer “MAIA Biotechnology, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-10-14 Raise Private raise (SEC Form D): $3.0M sold of $7.0M offered; issuer “MAIA Biotechnology, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-06-11 Raise Private raise (SEC Form D): $695K sold of $8.0M offered; issuer “MAIA Biotechnology, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-03-04 Raise Private raise (SEC Form D): $4.1M sold of $5.9M offered; issuer “MAIA Biotechnology, Inc.”. Verified from the SEC filing. SEC filing ↗
2024-11-12 Raise Private raise (SEC Form D): $2.4M sold of $15.5M offered; issuer “MAIA Biotechnology, Inc.”. Verified from the SEC filing. SEC filing ↗